Nasdaq

Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Mainz Biomed B.V. ( (MYNZ)) has ...
Nasdaq

Mainz Biomed Regains Compliance with Nasdaq Listing Requirements

Mainz Biomed NV has announced that it has regained compliance with Nasdaq's minimum stockholders’ equity requirement, confirming its continued listing on the Nasdaq Capital Market. This follows the ...
Benzinga.com

Mainz Biomed Partners With Liquid Biosciences In Exclusive Relationship To Harness The Power Of Artificial Intelligence (AI) To Develop Next-Generation Colorectal Screening Test

The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning ...
Seeking Alpha

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus On January 23, 2025, the Company received formal notice from Nasdaq confirming ...
Seeking Alpha

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Benzinga.com

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Mainz Biomed N.V. (NASDAQ:MYNZ) announced a 1-for-40 reverse stock split, effective Dec. 3. The company specializes in the early detection of cancer. Last month, Mainz Biomed reported a collaborative ...
News Medical

Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) ...
News Medical

Mainz Biomed to unveil breakthrough early cancer detection study results at DDW 2024

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in ...
Becker's ASC

Mainz Biomed debuts new colorectal cancer screening test

Molecular genetics diagnostic company Mainz (Germany) Biomed has submitted an application for breakthrough device designation from the FDA for a colorectal cancer screening test. If granted, the ...
Yahoo Finance

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Business Insider

EQS-News: Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting 28.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the content ...